858 Therapeutics
Covalent chemistry platform for irreversible small molecule inhibitors targeting cancer
- Sector
- Biotech
- Founded
- 2019
- Latest Form D
- $25.2M, Jul 2024
- Total capital
- $65.2M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $65.2M
- 3 Form D · last Jul 2024
- 28 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 11 pending · first 2024
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$25.2M
- Private capital raisedForm D · SEC · 2nd filing$20M
- Private capital raisedForm D · SEC · 1st filing$20.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- James VealResearcherExecutive OfficerLinked by 2 patents
- Ali BehbahaniDirectorNamed in SEC Form D filings
- Bradley J. BolzonDirectorNamed in SEC Form D filings
- Carlo RizzutoDirectorNamed in SEC Form D filings
- Clare OzawaDirectorNamed in SEC Form D filings
- Jane HuangDirectorNamed in SEC Form D filings
Show all 10 people
- Jeffrey A. StaffordExecutive Officer, DirectorNamed in SEC Form D filings
- Katherine Bell-McGuinnExecutive OfficerNamed in SEC Form D filings
- Monal MehtaDirectorNamed in SEC Form D filings
- Stafford JeffreyExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 13- GrantedSubstituted IMIDAZO[1,2-A]QUINAZOLINES As Inhibitors Of PargUSPTOUS 12,435,092
- Pending6,6-FUSED Heterocyclic Compounds As METTL3 InhibitorsUSPTOApplication 18718735
- PendingInhibitors Of Qpctl And QpctUSPTOApplication 18356166
Show all 13 patent records
- Substituted IMIDAZO[1,2-A]QUINAZOLINES As Inhibitors Of PargOct 7, 2025 · US 12,435,092Granted
- 6,6-FUSED Heterocyclic Compounds As METTL3 InhibitorsFeb 20, 2025 · Application 18718735Pending
- Inhibitors Of Qpctl And QpctMar 28, 2024 · Application 18356166Pending
- SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARGMar 26, 2024 · US 11,939,335Granted
- Inhibitors Of Qpctl And QpctApplication PCTUS2023070646Pending
- Inhibitors Of PargApplication PCTUS2023022390Pending
- 6,6-FUSED Heterocyclic Compounds As METTL3 InhibitorsApplication PCTUS2022082436Pending
- Inhibitors Of PargApplication 63343005Pending
- Inhibitors Of PargApplication PCTUS2024056940Pending
- 6,6-FUSED Heterocyclic Compounds As METTL3 InhibitorsApplication 63294674Pending
- Treatment Of Cancer With A Parg InhibitorApplication PCTUS2024056671Pending
- Inhibitors Of PargApplication 63602264Pending
- Treatment Of Cancer With A Parg InhibitorApplication 63601453Pending
Related companies, and why
- EPALEX CorpSimilar federal contract value in Biotech · null in contracts
- Cybrexa Holding Company, LLCSimilar federal contract value in Biotech · null in contracts
- KisoTerra Biotech Corp.Similar federal contract value in Biotech · null in contracts
- Remedy Plan, Inc.Similar federal contract value in Biotech · null in contracts
- Vyome Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- Pliant.io, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .